Carole Ho
Board Member
Royalty Pharma plc (RPRX)Equibles does not estimate personal net worth.
Get an email with a short summary when Royalty Pharma plc publishes a filing, an earnings call transcript or a press release.
Get RPRX alertsAbout Carole Ho
Carole Ho is recorded as Board Member at Royalty Pharma plc (RPRX) since July 17, 2025. Earlier roles on record: Board Member at Beam Therapeutics Inc. (BEAM) until February 27, 2026. Beam Therapeutics Inc. reported in an 8-K filed February 5, 2026 that Carole Ho resigned as Board of Directors, effective February 27, 2026. Royalty Pharma plc reported in an 8-K filed July 17, 2025 that Carole Ho was appointed member of the Board of Directors, effective July 17, 2025. The proxy statement of Denali Therapeutics Inc. reports total compensation of $3,828,870 for Carole Ho in fiscal 2025, including a base salary of $483,000. Disclosed compensation is on record for 9 fiscal years. Royalty Pharma plc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Royalty Pharma plc includes Pablo Legorreta (CEO), Vlad Coric (CEO and Board Member), Christopher Hite (Chairman) and 7 others.
“On January 31, 2026, Carole Ho provided Beam Therapeutics Inc. (the "Company") with notice of her resignation from the Board of Directors of the Company, effective as of February 27, 2026.”
“Effective July 17, 2025, Carole Ho and Elizabeth (Bess) Weatherman were appointed to serve as new members of the Board of Directors (the "Board") of Royalty Pharma plc (the "Company").”
Affiliation history
-
Current
2025-07-17–present
-
Royalty Pharma plc (RPRX)
Proxy statement
CurrentStart not stated–present
Last confirmed April 10, 2026
-
Start not stated–2026-02-27
-
Denali Therapeutics Inc. (DNLI)
Proxy statement
Start not stated–2025-11-14
Company network
Leadership on record at Royalty Pharma plc
- Pablo Legorreta CEO
- Vlad Coric CEO, Board Member
- Christopher Hite Chairman
- David Hodgson Chairman
- Gregory Norden CFO
- Terrance Coyne CFO
- Arthur McGivern General Counsel
- Arthur R. McGivern General Counsel
- Catherine Engelbert Board Member
- Dr. Vlad Coric Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Denali Therapeutics Inc. (DNLI) | Chief Medical Officer and Head of Development (until November 14, 2025) | $483,000 | $3,828,870 |
| 2024 | Denali Therapeutics Inc. (DNLI) | Chief Medical Officer | $535,600 | $4,022,759 |
| 2023 | Denali Therapeutics Inc. (DNLI) | Chief Medical Officer | $520,000 | $4,169,183 |
| 2022 | Denali Therapeutics Inc. (DNLI) | Chief Medical Officer | $500,000 | $5,692,052 |
| 2021 | Denali Therapeutics Inc. (DNLI) | Chief Medical Officer | $473,616 | $6,543,606 |
| 2020 | Denali Therapeutics Inc. (DNLI) | Chief Medical Officer | $457,600 | $4,325,347 |
| 2019 | Denali Therapeutics Inc. (DNLI) | Chief Medical Officer | $440,000 | $2,489,571 |
| 2018 | Denali Therapeutics Inc. (DNLI) | Chief Medical Officer | $423,124 | $3,935,469 |
| 2017 | Denali Therapeutics Inc. (DNLI) | Chief Medical Officer | $406,850 | $1,367,997 |